A diabetic patient at home has her diet and medication questions answered over the phone in a conversation with an AI healthcare agent. Another AI healthcare agent calls to check in with a patient ...

February 21, 2024, started like any ordinary day, but ended amid one of the most consequential cyberattacks in US history. It was an incident everyone in the healthcare industry feared, but few had ...

The health system’s electronic health records, MyChart patient portal and several systems for ordering tests and medications are unavailable, Ascension said.

The model, if finalized, will test whether putting hospitals on the hook for kidney transplant access and quality might improve the nation’s shoddy system of organ procurement and transplantation.

The incident at Ascension comes after other large cybersecurity events have hit the healthcare industry. Change Healthcare, a technology company owned by UnitedHealth Group, was hit by a cyberattack ...

Navina, the artificial intelligence (AI)-powered primary care platform that transforms complex, fragmented patient data into ...

The real estate investment trust reported nearly $700 million in impairments related to Steward alone in the first quarter. However, executives said rental agreements are not what drove the troubled ...

As more retailers seek healthcare customers, The Vitamin Shoppe is introducing a telehealth service called Whole Health Rx by The Vitamin Shoppe, the nutritional products retailer announced Wednesday.

Yale says Prospect allowed the conditions at three Connecticut hospitals — which it agreed to acquire in 2022 — to deteriorate. Prospect argues the lawsuit is an “11th hour attempt” to back out of the ...

Heightened antitrust scrutiny from state governments and regulators in Washington is having a chilling effect on deals, according to PitchBook analysts.

The University of Tennessee Health Science Center (UTHSC)-Campbell Clinic Orthopaedic Surgery Residency Program is proud to announce its 100th anniversary in 2024. Across the globe, more than 700 ...

The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.